Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Overview
China pharmaceutical distributor's interim revenue declined slightly year-on-year
Net income attributable to shareholders fell compared to the prior-year period
Company focused on operational quality, risk management and digital transformation
Outlook
Sinopharm Group did not provide specific financial guidance for the current or future periods in the press release
Result Drivers
OPERATIONAL QUALITY FOCUS - Co said it concentrated on improving operational quality and efficiency in the first half
RISK MANAGEMENT - Sinopharm Group highlighted risk management and control as a key task during the reporting period
DIGITAL TRANSFORMATION - Co said it prioritized digital transformation as part of its strategic initiatives
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| RMB 282.80 bln |
|
H1 Net Income Attributable |
| RMB 3.40 bln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Sinopharm Group Co Ltd is HK$22.80, about 36.9% above its August 21 closing price of HK$16.65
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 6 three months ago
Reuters Recommended Reads
Aug 21 - China's Henlius H1 revenue jumps on drug sales, license income
Aug 21 - China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distribution
Aug 20 - China's Brii Biosciences interim net loss narrows on lower R&D expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For